{"entity":{"id":"jean-charles-soria","kind":"person","name":"Jean-Charles Soria","aka":[],"tldr":"Ran the phase 1 unit that pioneered many targeted therapies, and led the FLAURA trial that made osimertinib first-line.","summary":"Jean-Charles Soria is Professor of Medicine at Paris-Saclay and a former Director General of Gustave Roussy. His specialisms are early drug development, EGFR-mutant lung cancer and phase 1 trials. He built the DITEP early-phase unit at Gustave Roussy, which pioneered many targeted therapies, and led FLAURA, the New England Journal of Medicine trial of osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer that made osimertinib the first-line standard. He later served as Director General and as an industry research and development leader before returning to academic medicine. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Soria%20JC%5BAuthor%5D%20osimertinib"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":["osimertinib"],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, Paris-Saclay; former Director General, Gustave Roussy","institutionId":"gustave-roussy","specialisms":["Early drug development","EGFR-mutant lung cancer","Phase 1 trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Soria%20JC%5BAuthor%5D%20osimertinib"}],"papers":[{"title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (FLAURA)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1713137"}],"orcid":"0000-0001-9597-0701"},"route":"/people/jean-charles-soria/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"institution":[{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/"}],"paper":[{"id":"paper-ascend-4-lancet-2017","kind":"paper","name":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","route":"/key-papers/paper-ascend-4-lancet-2017/"},{"id":"paper-flaura-nejm-2018","kind":"paper","name":"FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-flaura-nejm-2018/"}],"trial":[{"id":"nct01828099","kind":"trial","name":"ASCEND-4","route":"/trials/nct01828099/"},{"id":"flaura","kind":"trial","name":"FLAURA","route":"/trials/flaura/"}]}}